Beacon Therapeutics $75 million Series C financing round

Davis Polk advised Forbion Growth Opportunities Fund II and Forbion Ventures Fund VI in connection with their participation in Beacon Therapeutics’ $75 million Series C financing round. In addition to Forbion, new investors Life Sciences at Goldman Sachs Alternatives and Retinal Degeneration Fund, as well as existing investors Syncona Limited, Oxford Science Enterprises and Advent Life Sciences, participated in the round.

Beacon Therapeutics is a leading clinical-stage biotechnology company focused on the development of treatments of rare and prevalent ocular diseases. The funds raised in the Series C financing round will be used to complete the development and advance commercialization plans of Beacon Therapeutics’ lead program, laru-zova, a potential best-in-class gene therapy currently being investigated for the treatment of patients with X-linked retinitis pigmentosa (XLRP), as well as to help accelerate the development of additional pipeline candidates.

Forbion is a leading global venture capital firm with headquarters in Naarden, the Netherlands, and offices in Munich, Germany, and Boston. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies covering all stages of (bio)pharmaceutical drug development. In addition to its human health focus, Forbion also invests in planetary health solutions through its BioEconomy strategy.

The Davis Polk corporate team included partner Leo Borchardt, counsel Maxim Van de moortel and William Tong and associate Jack Spain. All members of the Davis Polk team are based in the London office.